Chargement...

Robocath in a few words

Robocath designs and develops innovative robotic solutions for improving endovascular procedures. In particular, these procedures are carried out to treat vascular diseases, including heart attacks, the leading cause of death worldwide.
Currently in the approval stage, the first solution developed by Robocath (R-One) will be launched early 2019 in Europe and the Middle East.
Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies in emergency reception centers from expert centers, guaranteeing the best care pathway for all.
Selected by Forbes magazine as the fourth medical start-up in France, Robocath has around 20 employees.

History

2009
Company foundation
2013
First in vivo tests
2014
ISO 13485 certification granted
2015
Industrial prototype
2017
Safety-Efficacy study
2019
R-One launch

Robocath in the world

19 Rue Marie Curie, Rouen, France
50 Milk Street, Boston, Massachusetts, États-Unis

Management

A doctor of medicine and a graduate of the 'Healthcare Industry Strategy and Management' program at ESSEC Business School, Philippe Bencteux has over twenty years of experience in vascular imaging. A trained neuro-radiologist, he founded Robocath in 2009 on the basis of the promising preliminary research carried out in collaboration with two engineering schools. He has since contributed his expertise in the medical sector to the company and is actively involved in the conception of new robotics solutions.
Bruno Fournier is a trained engineer (Supélec) and Doctor of Science (Université Paris VI), with strong R&D experience in the healthcare sector. He led the development of products with high added value in several fields (ultrasound, bone density measurement, respiratory support, etc.). Passionate about new medical technologies, he joined Robocath in 2012 after management roles with the Air Liquide Groupe and his time as Director of R&D at one of Getinge Group subsidiary from 2006 to 2012.

Strategic Committee

M Capital Partners is an independent and entrepreneurial French investment and financing company. It took a stake in Robocath in 2017.
Newly created by the CEA Investissement seasoned funds management team, CEA and Amundi, Supernova Invest is specialized in deep-tech venture capital in life sciences, energy and industry (electronics, advanced materials, instruments…).
Normandie Participations, an equity financing tool backed by AD Normandie, is a regional financing structure for equity participations in companies based in Normandy. The fund took a stake in Robocath in 2017.
An historic investor in Robocath (since 2013), NCI is a major player in capital investment in Normandy.
An historic investor in Robocath (since 2013), GO CAPITAL is an investment fund management company that favors companies with high growth potential in the fields of healthcare, technology (hardware and software), digital and innovative services.

Medical Advisory Board

Professor of medicine and former chief of the cardiology department at the university hospital of Rouen, conceived and developed the TAVI (Transcatheter Aortic Valve Implantation) procedure, a breakthrough, less invasive interventional treatment for structural heart diseases. Since its creation, the device has been implanted in thousands of patients around the world. He is the author of more than 600 publications and has received several major international medical and scientific awards.
• co-director of the cardiovascular disease department at the Clinique Pasteur in Toulouse, co-director of EuroPCR, one of the most important interventional cardiology congresses in the world. Director of the EAPCI, (European Association of Percutaneous Cardiovascular Interventions) between 2011 and 2014. He is the author of numerous publications and holds several major awards.
Head of the Villa Maria hospital cardiovascular department in Bologna (Italy) for the last 25 years, published many interventional cardiology and peripheral vascular papers. From 2011 to 2013, he was president of the Italian society of interventional cardiology. He has for many years been an active member of the PCR board and received several awards in recognition of his achievements.
professor of medicine and director of cardiovascular research and training at the Center for Interventional Therapy at Colombia University Medical Center and at the Cardiovascular Research Foundation, both in New York. Regularly engaged in clinical research and professional education, he has led and published more than 2,000 manuscripts and abstracts and has received several major awards for his work. He is director of the TCT Congress (Transcatheter Cardiovascular Therapeutics), one of the largest interventional cardiology gatherings in the world.

Awards

Rated as fourth Medical French Start-up
by Forbes Magazine
Winner of the TechInnov Award 2015

Partners